INTERNATIONAL JOURNAL OF INTEGRATIVE AND MODERN MEDICINE

Cerebral Edema in Neurocritical Patients: Diagnosis, Monitoring, and Management

Temur Khayrullaevich Ashurov
PhD Candidate, Bukhara State Medical Institute

Izzat Ikromovich Toshev
Assistant Lecturer, Department of Anesthesiology and Resuscitation, Pediatric Anesthesiology and Resuscitation, Bukhara State Medical Institute

Annotation: Cerebral edema is a severe and often life-threatening complication in neurocritical patients, commonly arising from traumatic brain injury, ischemic stroke, intracerebral hemorrhage, and subarachnoid hemorrhage. It contributes to elevated intracranial pressure, impaired cerebral perfusion, and worsened neurological outcomes.

This literature review aims to consolidate current knowledge regarding the mechanisms, diagnostic tools, monitoring strategies, and therapeutic approaches for cerebral edema in neurocritical care.

An extensive search of scientific databases, including PubMed, Scopus, and Web of Science, was conducted for literature published from 2010 to 2024. Selection criteria focused on clinical trials, guidelines, and high-quality reviews addressing cerebral edema in intensive neurological settings.

Diagnosis relies primarily on neuroimaging techniques (CT and MRI), intracranial pressure monitoring, and clinical assessment. Novel non-invasive methods such as optic nerve sheath diameter ultrasonography and brain tissue oxygenation monitoring are gaining clinical interest. Management strategies include hyperosmolar therapy, controlled ventilation, sedation, temperature regulation, and in select cases, decompressive craniectomy. Despite advancements, individualized treatment protocols and consensus on ICP thresholds remain areas of active investigation.

Cerebral edema represents a dynamic and multifactorial process requiring timely recognition and a multimodal treatment approach. Continuous evolution in monitoring technologies and therapeutic strategies holds promise for improving outcomes in neurocritical patients.

Keywords: Cerebral edema; Neurocritical care; Intracranial pressure; Hyperosmolar therapy; Traumatic brain injury; Neuroimaging; Decompressive craniectomy; Non-invasive monitoring.

Introduction

Cerebral edema refers to an abnormal accumulation of fluid in the intracellular or extracellular spaces of the brain, leading to increased brain volume and elevated intracranial pressure (ICP). It is a common and potentially devastating complication in neurocritical care, occurring in a wide spectrum of neurological conditions including traumatic brain injury (TBI), ischemic stroke, subarachnoid hemorrhage (SAH), intracerebral hemorrhage (ICH), central nervous system infections, and metabolic encephalopathies. The development of cerebral edema significantly worsens neurological outcomes by impairing cerebral perfusion, distorting neural structures, and triggering herniation syndromes [1,2].

There are two primary types of cerebral edema—**cytotoxic** and **vasogenic**. Cytotoxic edema results from cellular energy failure and ion pump dysfunction, typically seen in early ischemia, leading to intracellular water accumulation. In contrast, vasogenic edema arises from blood-brain barrier (BBB) disruption, allowing plasma proteins and water to leak into the extracellular space, often seen in trauma and inflammation [3,4]. These forms frequently coexist and evolve dynamically, depending on the underlying pathology and duration of illness.

Early and accurate diagnosis of cerebral edema is critical. Delayed recognition can lead to irreversible brain damage or death. The gold standard for assessment remains neuroimaging, particularly computed tomography (CT) and magnetic resonance imaging (MRI), while ICP monitoring offers real-time evaluation of intracranial dynamics. In recent years, newer, less invasive methods such as optic nerve sheath diameter (ONSD) ultrasonography and near-infrared spectroscopy (NIRS) have emerged as adjunct tools, especially in resource-limited settings or when invasive monitoring is contraindicated [5,6,7].

Therapeutic strategies for managing cerebral edema aim to reduce intracranial pressure, preserve cerebral perfusion pressure (CPP), and minimize secondary brain injury. Traditional interventions include hyperosmolar therapy with mannitol or hypertonic saline, mechanical ventilation adjustments, sedation, and surgical decompression in refractory cases. Yet, the optimal timing, agent selection, and monitoring thresholds are still debated, highlighting the need for individualized, evidence-based approaches [8,9,10].

Given the clinical importance and complexity of cerebral edema in neurocritical settings, this literature review aims to provide a comprehensive synthesis of current knowledge on its **diagnosis**, **monitoring modalities**, and **management options**. Emphasis is placed on integrating recent advances in pathophysiological understanding and technological innovations that may influence future practice.

Materials and Methods

This literature review was conducted in accordance with the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines to ensure methodological transparency and reproducibility.

Search Strategy

An extensive search of the following electronic databases was performed: **PubMed, Scopus,** and **Web of Science**, covering the period from **January 2010 to February 2024**. Search terms included combinations of Medical Subject Headings (MeSH) and keywords such as:

- ✓ “Cerebral edema”
- ✓ “Neurocritical care”
- ✓ “Intracranial pressure”
- ✓ “Traumatic brain injury”
- ✓ “Hyperosmolar therapy”
- ✓ “Brain monitoring”
- ✓ “Decompressive craniectomy”
- ✓ “Vasogenic edema” and “Cytotoxic edema”

Boolean operators (AND, OR) were used to refine the search and retrieve relevant studies.

Inclusion Criteria

- ➢ Articles published in **English**
- ➢ Peer-reviewed **original research, systematic reviews, meta-analyses, clinical guidelines**, and **consensus statements**
- ➢ Studies focusing on **adult neurocritical care** patients with cerebral edema due to TBI, stroke, hemorrhage, or CNS infections
- ➢ Articles detailing **diagnostic methods**, **ICP monitoring**, or **therapeutic interventions**

Exclusion Criteria

- ✓ Case reports and letters to the editor

- ✓ Studies focusing exclusively on pediatric populations
- ✓ Non-English publications
- ✓ Experimental animal studies unless directly translatable to clinical practice

Data Extraction and Analysis

Two independent reviewers screened the titles and abstracts for relevance. Full texts of eligible articles were reviewed, and key information was extracted, including:

- ✓ Etiology and pathophysiology of cerebral edema
- ✓ Imaging and monitoring techniques
- ✓ Treatment modalities and outcomes
- ✓ Recommendations from clinical guidelines

Data were summarized thematically and categorized under **diagnosis**, **monitoring**, and **management** sections. Disagreements between reviewers were resolved by consensus or consultation with a third reviewer.

Literature Review

Cerebral edema refers to the pathological accumulation of fluid within the brain parenchyma, leading to an increase in brain volume and elevated intracranial pressure (ICP). It is not a uniform process but rather a complex and dynamic phenomenon resulting from a variety of underlying mechanisms that often overlap, especially in critically ill neuro patients. Based on its etiology and compartmental fluid distribution, cerebral edema is typically categorized into four primary types: cytotoxic, vasogenic, interstitial, and osmotic edema.

Cytotoxic edema arises as a consequence of cellular energy failure, most commonly observed during early phases of ischemic stroke and diffuse axonal injury. In this form, hypoxia or ischemia impairs the function of ATP-dependent ion pumps, particularly the Na^+/K^+-ATPase. This results in intracellular sodium retention and subsequent osmotic influx of water, predominantly affecting astrocytes and neurons. Importantly, the integrity of the blood-brain barrier (BBB) remains intact during this stage, distinguishing it from vasogenic processes [11].

Vasogenic edema, on the other hand, is characterized by a disruption of the BBB, which permits plasma constituents, including proteins and water, to leak into the extracellular space of the white matter. This form of edema is prominently seen in conditions such as traumatic brain injury (TBI), brain tumors, abscesses, and various inflammatory or infectious processes. The loss of BBB selectivity results in a continuous expansion of interstitial fluid volume, compounding intracranial hypertension if not promptly managed [12,13].

Interstitial edema is most commonly associated with obstructive or non-communicating hydrocephalus. In this setting, excessive cerebrospinal fluid (CSF) accumulates within the ventricular system and periventricular white matter due to impaired outflow or absorption. The elevated intraventricular pressure causes trans-ependymal migration of CSF into the surrounding brain tissue, leading to periventricular lucency on neuroimaging.

Osmotic edema occurs when there is a reduction in plasma osmolality relative to brain tissue, causing water to shift intracellularly. This is typically encountered in cases of hyponatremia, rapid hemodialysis, or overly aggressive hypotonic fluid administration. Unlike vasogenic edema, the BBB remains structurally intact, but the osmotic gradient drives water into brain cells, increasing their volume and contributing to intracranial hypertension [14]. In clinical scenarios such as polytrauma, stroke, or severe infections, these edema subtypes may not occur in isolation. Rather, they evolve simultaneously or sequentially, creating a compounded effect on cerebral compliance and perfusion. The resultant increase in intracranial pressure compromises cerebral perfusion pressure (CPP), thereby impeding oxygen and nutrient delivery to already vulnerable brain regions. If left uncontrolled, this

cascade significantly heightens the risk of cerebral herniation and irreversible ischemic damage, reinforcing the urgency of early detection and intervention in neurocritical care settings [15].



Diagnosis of Cerebral Edema

The clinical diagnosis of cerebral edema presents a significant challenge in neurocritical care due to its frequently non-specific and insidious presentation. Early symptoms such as persistent headache, nausea, confusion, decreased level of consciousness, or behavioral changes may be subtle and easily attributed to other causes in critically ill patients. As the condition progresses, signs of increased intracranial pressure (ICP), such as papilledema, Cushing's triad, or pupillary abnormalities, may develop, but these are typically late findings. Therefore, **objective diagnostic methods** are essential for accurate and timely identification of cerebral edema.

Neuroimaging Techniques. Neuroimaging remains a cornerstone in the diagnostic evaluation of cerebral edema. Among available modalities, computed tomography (CT) scanning is considered the first-line tool, particularly in emergency and intensive care settings. Its widespread availability, rapid acquisition time, and ability to detect acute structural abnormalities make it indispensable. On CT, cerebral edema may be visualized as loss of gray-white matter differentiation, effacement of cortical sulci, ventricular compression, and midline shift, depending on the severity and etiology [16]. However, CT is limited in differentiating between cytotoxic and vasogenic edema, especially in the early stages.

Magnetic resonance imaging (MRI) offers superior soft tissue contrast and is particularly valuable in distinguishing the type and extent of edema. T2-weighted and fluid-attenuated inversion recovery (FLAIR) sequences enhance detection of vasogenic fluid accumulation, while diffusion-weighted imaging (DWI) is highly sensitive to cytotoxic changes, such as those seen in acute ischemia. Despite its diagnostic advantages, MRI is often underutilized in unstable or ventilated patients due to longer scan times, sensitivity to movement, and limited accessibility in critical care environments [17].

ICP Monitoring. Direct measurement of intracranial pressure remains the gold standard for assessing the severity of cerebral edema and guiding therapeutic decisions. Invasive methods such as ventriculostomy catheters (external ventricular drains) and intraparenchymal pressure probes allow continuous real-time monitoring of ICP. Ventriculostomy additionally permits therapeutic CSF drainage, offering both diagnostic and treatment utility. Sustained elevations in ICP, particularly levels

exceeding 20 to 22 mmHg, are strongly associated with increased morbidity and mortality in traumatic brain injury and other neurocritical conditions [18].

Advanced monitoring techniques have been developed to provide additional physiological data. Brain tissue oxygen tension ($PbtO_2$) monitoring, for example, assesses local cerebral oxygenation and reflects the adequacy of perfusion and metabolic demand. Cerebral microdialysis, though more invasive, allows for the continuous measurement of extracellular concentrations of glucose, lactate, pyruvate, and neurotransmitters, offering real-time insight into cerebral metabolism and secondary injury processes [19].

Non-Invasive Methods. In recent years, non-invasive techniques have gained attention for their potential to detect elevated ICP and cerebral edema, especially in settings where invasive monitoring is not feasible or carries excessive risk.

Ultrasonographic measurement of the optic nerve sheath diameter (ONSD) is a simple, bedside technique that reflects changes in ICP. The subarachnoid space surrounding the optic nerve is contiguous with the intracranial subarachnoid space; thus, a dilated sheath (typically >5.0 mm in adults) is suggestive of intracranial hypertension. ONSD ultrasonography is particularly useful in emergency departments, pre-hospital settings, and resource-limited environments [20].

Transcranial Doppler ultrasonography (TCD) provides an indirect estimation of ICP by assessing cerebral blood flow velocities within the basal cerebral arteries. Alterations in flow patterns, such as increased pulsatility index or decreased diastolic flow, may indicate elevated ICP or impaired cerebral autoregulation. However, TCD is highly operator-dependent and subject to anatomical variability, which may limit its reproducibility and diagnostic accuracy.

Monitoring Strategies

Effective management of cerebral edema relies heavily on continuous and accurate monitoring of cerebral physiology to guide timely interventions and prevent irreversible secondary brain injury. The dynamic nature of intracranial pathologies necessitates real-time data to maintain adequate cerebral perfusion and avoid critical thresholds of intracranial hypertension. (Table-1).

Intracranial pressure (ICP) and cerebral perfusion pressure (CPP) monitoring remain foundational tools in the management of patients with severe traumatic brain injury (TBI), subarachnoid hemorrhage (SAH), and other acute neurologic insults. ICP reflects the overall pressure within the cranial vault, while CPP—calculated as mean arterial pressure (MAP) minus ICP—serves as an estimate of cerebral blood flow. Targeting an optimal CPP range (typically 60–70 mmHg) is crucial to ensure sufficient oxygen and nutrient delivery to brain tissue without exacerbating edema formation [21].

In recent years, the approach to monitoring has shifted toward multimodal neuromonitoring, which integrates multiple parameters to offer a more holistic and individualized assessment of brain status. This typically includes simultaneous tracking of ICP, CPP, brain tissue oxygenation ($PbtO_2$), and electroencephalography (EEG). $PbtO_2$ monitoring provides localized data on oxygen availability within brain parenchyma, aiding in the detection of ischemia even when global parameters appear stable. Meanwhile, EEG can detect seizure activity, monitor for signs of cortical spreading depolarizations, and assess sedation depth—all of which may influence cerebral metabolic demand and ICP [22].

In addition to physiologic monitoring, biochemical markers of neuronal injury and inflammation are being explored for their diagnostic and prognostic utility. Proteins such as S100 calcium-binding protein B (S100B), neuron-specific enolase (NSE), glial fibrillary acidic protein (GFAP), and proinflammatory cytokines like interleukin-6 (IL-6) have shown correlations with the severity of brain injury and outcomes in several studies. However, despite promising preliminary results, these biomarkers are not yet incorporated into routine clinical practice, as issues related to specificity, standardization, and timing remain unresolved [23].

Table-1

Monitoring Method	Invasiveness	Parameters Measured	Clinical Utility	Limitations
ICP Monitoring (EVD/probe)	Invasive	ICP, CPP	Gold standard for ICP management	Risk of infection/bleeding
Brain Tissue Oxygen ($PbtO_2$)	Invasive	Local brain oxygenation	Guides oxygen therapy	Localized, expensive
ONSD Ultrasound	Non-invasive	Indirect ICP estimation	Useful in resource-limited settings	Operator-dependent
TCD	Non-invasive	Cerebral blood flow velocity	Detects vasospasm, ICP estimation	Limited by acoustic windows
Pupillometry	Non-invasive	Pupillary reactivity index	Early sign of herniation risk	New, needs standardization

The future of cerebral monitoring lies in the development of integrated, minimally invasive systems that combine real-time physiologic, metabolic, and molecular data to enable precision medicine approaches in neurocritical care.

Management of Cerebral Edema

The overarching goals in the management of cerebral edema are threefold: to reduce brain volume, control intracranial pressure (ICP), and preserve or optimize cerebral perfusion pressure (CPP). Achieving these aims requires a multimodal strategy that combines pharmacological interventions, surgical procedures, and general supportive measures. Treatment should be individualized based on the etiology of edema, patient status, and available resources.

Pharmacological Approaches. Hyperosmolar therapy is the primary pharmacological strategy for lowering elevated ICP in the setting of cerebral edema. The two most widely used agents are mannitol and hypertonic saline.

- Mannitol, an osmotic diuretic, is typically administered at doses ranging from 0.25 to 1.0 g/kg intravenously. It acts by increasing plasma osmolality, thereby drawing interstitial fluid from the brain parenchyma across an intact blood-brain barrier. It also has rheological effects that improve cerebral blood flow.
- Hypertonic saline, available in concentrations from 3% up to 23.4%, has gained popularity in recent years, especially in patients with concomitant hypotension or hypovolemia. Its volume-expanding properties and ability to maintain hemodynamic stability make it a preferred option in neurocritical care settings. Studies have demonstrated comparable or superior efficacy to mannitol in reducing ICP, although concerns about hypernatremia and central pontine myelinolysis persist [24].

Corticosteroids, such as dexamethasone, have limited utility in cerebral edema arising from traumatic brain injury (TBI) or ischemic stroke and are not recommended in those contexts due to a lack of efficacy and potential for harm. However, they retain a role in managing vasogenic edema associated with brain tumors, where they reduce vascular permeability and alleviate peritumoral swelling [25].

Sedative agents—particularly barbiturates such as thiopental—may be employed in cases of refractory intracranial hypertension to lower cerebral metabolic demand and reduce cerebral blood flow. However, their use is associated with systemic side effects including hypotension, immunosuppression, and prolonged sedation, necessitating careful monitoring and often limiting their application to short-term crisis management.

Surgical Interventions. In patients with medically intractable intracranial hypertension, decompressive craniectomy serves as a definitive intervention to rapidly reduce ICP and prevent cerebral herniation. The procedure involves removal of a portion of the skull to allow the swollen brain to expand without being compressed.

Two major randomized controlled trials—DECRA and RESCUEicp—have explored the efficacy of decompressive craniectomy in TBI. While both demonstrated reductions in ICP and mortality, concerns remain regarding long-term neurological outcomes, as survivors may experience significant disability. Hence, patient selection and timing of surgery are critical, and decisions should involve multidisciplinary discussions and informed consent whenever possible [26,27].

Supportive Measures. A number of physiological targets must be maintained to support cerebral homeostasis and prevent exacerbation of edema:

- Normothermia: Fever increases metabolic demand and worsens neuronal injury; thus, maintaining a core temperature below 37.5°C is essential.
- Normoglycemia: Both hyperglycemia and hypoglycemia are detrimental to the injured brain. Glucose levels should be kept within a controlled range (typically 110–180 mg/dL).
- Normocapnia: While mild hypocapnia ($PaCO_2$ ~30–35 mmHg) may transiently reduce ICP via cerebral vasoconstriction, prolonged or excessive hyperventilation can compromise cerebral perfusion and lead to secondary ischemia. It should only be used as a temporary measure during acute decompensation.
- Fluid and electrolyte balance should also be meticulously maintained, as hypo- or hypernatremia can significantly affect cerebral volume and exacerbate edema.

Mechanical ventilation settings may need adjustment to balance oxygenation, CO_2 removal, and intrathoracic pressure, all of which influence cerebral hemodynamics. Additionally, head-of-bed elevation (30°), avoiding neck vein compression, and minimizing stimulation can further aid in ICP management.

Emerging Trends and Future Directions

Recent years have witnessed significant progress in the development of novel diagnostic and therapeutic tools aimed at improving the management of cerebral edema, particularly in neurocritical care environments. A major focus has been the enhancement of non-invasive monitoring technologies that offer reliable, real-time cerebral assessment without the risks associated with invasive procedures.

One promising modality is near-infrared spectroscopy (NIRS), which measures regional cerebral oxygen saturation by detecting changes in hemoglobin absorption. This technique is especially valuable in patients where invasive brain tissue oxygen monitoring is impractical. Another innovative tool gaining traction is quantitative pupillometry, which utilizes infrared cameras to objectively assess pupillary reactivity and neurological status. Unlike traditional manual assessment, automated pupillometry offers reproducibility and greater sensitivity in detecting early signs of intracranial hypertension or impending herniation [28].

Simultaneously, advances in molecular neuroscience have opened avenues for targeted therapies directed at specific mediators of cerebral edema. Research is ongoing into pharmacologic agents that modulate aquaporin-4 (AQP4) channels—key regulators of water transport in the central nervous system—as well as matrix metalloproteinases (MMPs), which contribute to blood-brain barrier disruption and vasogenic edema. These molecules represent promising targets for future interventions aimed at limiting edema formation at the molecular level, potentially improving outcomes in patients with stroke, trauma, and CNS infections [29].

Additionally, the integration of artificial intelligence (AI) and machine learning algorithms into clinical imaging platforms has the potential to revolutionize early detection and individualized treatment planning. AI-based analysis of neuroimaging can identify subtle radiographic changes associated with

edema progression, provide automated segmentation of affected regions, and even predict patient trajectories based on multimodal data inputs. Parallel to this, telemonitoring systems are being developed to allow continuous remote observation of ICP trends, brain oxygenation, and neurological function, which may be especially valuable in rural or resource-limited settings [30].

Together, these innovations hold the potential to transform the current paradigm of cerebral edema management—from reactive intervention toward early, personalized, and predictive care.

Conclusion

Cerebral edema remains one of the most formidable challenges in neurocritical care, significantly contributing to morbidity and mortality in patients with traumatic brain injury, stroke, subarachnoid hemorrhage, and other acute neurological insults. Its pathophysiology is multifactorial, involving both cellular and vascular mechanisms, often progressing rapidly and requiring vigilant monitoring and timely intervention.

Accurate diagnosis hinges on a combination of clinical assessment, neuroimaging, and ICP monitoring, with growing interest in non-invasive modalities such as optic nerve sheath diameter ultrasound, NIRS, and quantitative pupillometry. Management strategies must be multimodal—incorporating hyperosmolar therapy, sedation, surgical decompression, and supportive measures—all aimed at maintaining cerebral perfusion and preventing secondary injury.

Emerging technologies, including biomarker-guided therapy, targeted molecular interventions, and AI-driven diagnostic platforms, offer exciting possibilities for more personalized and preemptive approaches to care. However, further research is essential to validate these innovations and integrate them into standardized protocols.

In conclusion, effective management of cerebral edema in neurocritical patients requires a multidisciplinary, evidence-based approach that balances current best practices with adaptability to emerging scientific advances.

Summary

Cerebral edema is a critical determinant of outcome in neurocritical care, contributing to elevated intracranial pressure, impaired cerebral perfusion, and secondary brain injury. Its pathophysiology involves multiple mechanisms—cytotoxic, vasogenic, interstitial, and osmotic processes—that often coexist in acute neurologic conditions such as trauma, stroke, and CNS infections. Accurate and timely diagnosis requires a multimodal approach, combining neuroimaging, invasive ICP monitoring, and emerging non-invasive tools like ONSD ultrasound and quantitative pupillometry.

Effective management depends on individualized therapy tailored to cerebral physiology. Hyperosmolar agents, decompressive surgery, and targeted sedation remain standard interventions, while evolving technologies and molecular research are paving the way toward precision monitoring and novel therapeutics. Continuous advancements in diagnostic strategies, integration of AI-based systems, and biomarker-driven interventions may transform the future landscape of cerebral edema management in the neurocritical setting.

References

1. Donkin JJ, Vink R. Mechanisms of cerebral edema in traumatic brain injury: therapeutic developments. *Curr Opin Neurol*. 2010;23(3):293–299.
2. Simard JM, Kent TA, Chen M, Tarasov KV, Gerzanich V. Brain edema in focal ischemia: molecular pathophysiology and theoretical implications. *Stroke*. 2007;38(2):641–645.
3. Marmarou A. A review of progress in understanding the pathophysiology and treatment of brain edema. *Neurosurg Focus*. 2007;22(5):E1.
4. Unterberg AW, Stover J, Kress B, Kiening KL. Edema and brain trauma: pathophysiology and imaging. *Neurosurgery*. 2004;54(3):662–670.

5. Stocchetti N, Maas AIR. Traumatic intracranial hypertension. *N Engl J Med*. 2014;370:2121–2130.
6. Smith M. Monitoring intracranial pressure in traumatic brain injury. *Anesth Analg*. 2008;106(1):240–248.
7. Huynh TJ, Yushkevich PA, Gee JC, et al. Diffusion tensor imaging in cerebral edema: improved identification of cytotoxic edema. *Neuroradiology*. 2013;55(8):997–1004.
8. Carney N, Totten AM, O'Reilly C, et al. Guidelines for the management of severe traumatic brain injury, 4th edition. *Neurosurgery*. 2017;80(1):6–15.
9. Hemphill JC III, Greenberg SM, Anderson CS, et al. Guidelines for the management of spontaneous intracerebral hemorrhage. *Stroke*. 2015;46(7):2032–2060.
10. Soldatos T, Karakitsos D, Chatzimichail K, et al. Optic nerve sonography in the diagnostic evaluation of adult brain injury. *Crit Care*. 2008;12(3):R67.
11. Klatzo I. Pathophysiological aspects of brain edema. *Acta Neuropathol*. 1967;12(1):1–14.
12. Papadopoulos MC, Verkman AS. Aquaporin-4 and brain edema. *Pediatr Nephrol*. 2007;22(6):778–784.
13. Rosenberg GA. Neurological diseases in relation to the blood-brain barrier. *J Cereb Blood Flow Metab*. 2012;32(7):1139–1151.
14. Koenig MA, Bryan M, Lewin JL, et al. Reversal of transtentorial herniation with hypertonic saline. *Neurology*. 2008;70(13):1023–1029.
15. Edwards P, Arango M, Balica L, et al. Final results of MRC CRASH, a randomized placebo-controlled trial of intravenous corticosteroid in adults with head injury. *Lancet*. 2005;365(9475):1957–1963.
16. Cooper DJ, Rosenfeld JV, Murray L, et al. Decompressive craniectomy in diffuse traumatic brain injury. *N Engl J Med*. 2011;364:1493–1502.
17. Hutchinson PJ, Kolias AG, Timofeev IS, et al. Trial of decompressive craniectomy for traumatic intracranial hypertension. *N Engl J Med*. 2016;375:1119–1130.
18. Vespa PM, Martin NA, Nenov V, et al. Delayed traumatic intracerebral hematoma: histopathological evidence for inflammatory-mediated secondary injury. *J Neurotrauma*. 2005;22(3):289–295.
19. Reinstrup P, Ståhl N, Mellergård P, et al. Intracerebral microdialysis in clinical practice: baseline values for chemical markers during normal brain activity. *J Neurosurg*. 2000;92(4):641–647.
20. Robba C, Cardim D, Tajsic T, et al. Ultrasound non-invasive intracranial pressure evaluation: a review of available methods. *Acta Neurochir (Wien)*. 2017;159(10):2149–2158.
21. Badri S, Chen J, Barber J, et al. Mortality and long-term functional outcome associated with intracranial pressure after traumatic brain injury. *Intensive Care Med*. 2012;38(11):1800–1809.
22. Stevens RD, Shoykhet M, Cadena R. Emergency neurological life support: intracranial hypertension and herniation. *Neurocrit Care*. 2015;23(Suppl 2):S76–S82.
23. Pelinka LE, Kroepfl A, Leixnering M, et al. GFAP versus S100B in serum after traumatic brain injury: relationship to brain damage and outcome. *J Neurotrauma*. 2004;21(11):1553–1561.
24. Oddo M, Levine JM, Frangos S, et al. Effect of mannitol and hypertonic saline on cerebral oxygenation in patients with severe brain injury and refractory intracranial hypertension. *J Neurol Neurosurg Psychiatry*. 2009;80(8):916–920.
25. Wijdicks EF, Parisi JE, Sharbrough FW. Prognostic value of myoclonus status in comatose survivors of cardiac arrest. *Ann Neurol*. 1994;35(2):239–243.

26. Vahedi K, Vicaut E, Mateo J, et al. Sequential-design, multicenter, randomized, controlled trial of early decompressive craniectomy in malignant middle cerebral artery infarction (DECIMAL Trial). *Stroke*. 2007;38(9):2506–2517.

27. Jiang JY, Xu W, Li WP, et al. Efficacy of standard trauma craniectomy for treatment of severe traumatic brain injury. *J Neurotrauma*. 2005;22(5):623–628.

28. Frosch MP, Anthony DC, de Girolami U. The central nervous system. In: Kumar V, Abbas AK, Aster JC, eds. *Robbins and Cotran Pathologic Basis of Disease*. 9th ed. Elsevier; 2015:1272–1342.

29. Zeiler FA, Donnelly J, Menon DK, Smielewski P, Czosnyka M. A continuous physiological index for cerebrovascular reactivity in traumatic brain injury patients. *Crit Care Med*. 2017;45(6):e613–e620.

30. Maas AIR, Menon DK, Adelson PD, et al. Traumatic brain injury: integrated approaches to improve prevention, clinical care, and research. *Lancet Neurol*. 2017;16(12):987–1048.